Announcement

Collapse
No announcement yet.

Cureus . Rapid Resolution of Post-COVID-19 Inflammatory Syndrome in an Adult With Targeted Inhibition of Interleukin-1B

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Cureus . Rapid Resolution of Post-COVID-19 Inflammatory Syndrome in an Adult With Targeted Inhibition of Interleukin-1B


    Cureus


    . 2022 Nov 30;14(11):e32078.
    doi: 10.7759/cureus.32078. eCollection 2022 Nov.
    Rapid Resolution of Post-COVID-19 Inflammatory Syndrome in an Adult With Targeted Inhibition of Interleukin-1B


    Mario Felix 1 , Larabe Farrukh 2 , Simple Modi 3 , Ruben Peredo-Wende 4



    Affiliations

    Abstract

    Multisystem inflammatory syndrome (MIS) is a severe inflammatory response that occurs days to weeks following the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). Initially known in children and named MIS-C, recently several cases of MIS in adults have been reported to the Centers for Disease Control and Prevention (CDC), leading to the recognition of a new disease MIS in adults (MIS-A). The current treatment options include high-dose steroids, intravenous immunoglobulin (IVIG), and immunosuppressive therapy. However, the pharmacologic approach remains limited to case reports and pending official guidelines to treat cases with MIS-A. We present a case of an adult patient who had a severe inflammatory state following COVID-19 infection, who was treated with IL-1 antagonist therapy with a successful outcome.

    Keywords: acute rheumatology; biologic agents; covid 19; interleukin-1β inhibitor; multisystem inflammatory syndrome in adult.

Working...
X